OBJECTIVES: To investigate the relation of plasma levels of Abeta peptides (Abeta1-40 and Abeta1-42) and apolipoprotein E (APOE) genotype to dementia status, and the duration of Alzheimer's disease (AD) in adults with Down syndrome (DS). METHODS: Adults with DS were recruited from community settings and followed up for a mean period of 6.7 years. Plasma levels Abeta1-40 and Abeta1-42 and APOE genotype were determined at the last visit. RESULTS: There were 83 nondemented participants and 44 participants with prevalent AD. Overall, plasma levels of Abeta1-42, Abeta1-40 and the ratio Abeta1-42/Abeta1-40 did not differ significantly between the adults with DS. Among demented participants, the mean level of Abeta1-40 was significantly lower (157.0 vs. 195.3) and the ratio of Abeta1-42/Abeta1-40 was significantly higher (0.28 vs. 0.16) in those with more than 4 years duration of dementia than in those with 4 or fewer years' duration of dementia. This pattern was generally similar in those with and without an APOE epsilon4 allele. CONCLUSIONS: There is an association between plasma Abeta peptide levels and the duration of AD in older persons with DS. The predictive and diagnostic roles of Abeta1-42 and Abeta1-40 measurements for AD, however, remain controversial. Change in Abeta peptide levels with onset of AD and with the duration of dementia may account for a lack of difference between prevalent cases and nondemented individuals and for variation in the predictive power of Abeta peptide levels.
OBJECTIVES:To investigate the relation of plasma levels of Abeta peptides (Abeta1-40 and Abeta1-42) and apolipoprotein E (APOE) genotype todementia status, and the duration of Alzheimer's disease (AD) in adults with Down syndrome (DS). METHODS: Adults with DS were recruited from community settings and followed up for a mean period of 6.7 years. Plasma levels Abeta1-40 and Abeta1-42 and APOE genotype were determined at the last visit. RESULTS: There were 83 nondemented participants and 44 participants with prevalent AD. Overall, plasma levels of Abeta1-42, Abeta1-40 and the ratio Abeta1-42/Abeta1-40 did not differ significantly between the adults with DS. Among demented participants, the mean level of Abeta1-40 was significantly lower (157.0 vs. 195.3) and the ratio of Abeta1-42/Abeta1-40 was significantly higher (0.28 vs. 0.16) in those with more than 4 years duration of dementia than in those with 4 or fewer years' duration of dementia. This pattern was generally similar in those with and without an APOE epsilon4 allele. CONCLUSIONS: There is an association between plasma Abeta peptide levels and the duration of AD in older persons with DS. The predictive and diagnostic roles of Abeta1-42 and Abeta1-40 measurements for AD, however, remain controversial. Change in Abeta peptide levels with onset of AD and with the duration of dementia may account for a lack of difference between prevalent cases and nondemented individuals and for variation in the predictive power of Abeta peptide levels.
Authors: L P Fried; R A Kronmal; A B Newman; D E Bild; M B Mittelmark; J F Polak; J A Robbins; J M Gardin Journal: JAMA Date: 1998-02-25 Impact factor: 56.272
Authors: N Schupf; B Patel; W Silverman; W B Zigman; N Zhong; B Tycko; P D Mehta; R Mayeux Journal: Neurosci Lett Date: 2001-04-06 Impact factor: 3.046
Authors: T Kosaka; M Imagawa; K Seki; H Arai; H Sasaki; S Tsuji; A Asami-Odaka; T Fukushima; K Imai; T Iwatsubo Journal: Neurology Date: 1997-03 Impact factor: 9.910
Authors: R Mayeux; M X Tang; D M Jacobs; J Manly; K Bell; C Merchant; S A Small; Y Stern; H M Wisniewski; P D Mehta Journal: Ann Neurol Date: 1999-09 Impact factor: 10.422
Authors: J K Teller; C Russo; L M DeBusk; G Angelini; D Zaccheo; F Dagna-Bricarelli; P Scartezzini; S Bertolini; D M Mann; M Tabaton; P Gambetti Journal: Nat Med Date: 1996-01 Impact factor: 53.440
Authors: S Craft; L Teri; S D Edland; W A Kukull; G Schellenberg; W C McCormick; J D Bowen; E B Larson Journal: Neurology Date: 1998-07 Impact factor: 9.910
Authors: Maria E Conidi; Livia Bernardi; Gianfranco Puccio; Nicoletta Smirne; Maria G Muraca; Sabrina A M Curcio; Rosanna Colao; Paola Piscopo; Maura Gallo; Maria Anfossi; Francesca Frangipane; Alessandra Clodomiro; Maria Mirabelli; Franca Vasso; Chiara Cupidi; Giusi Torchia; Raffaele Di Lorenzo; Paola Mandich; Annamaria Confaloni; Raffaele G Maletta; Amalia C Bruni Journal: Neurology Date: 2015-05-06 Impact factor: 9.910
Authors: Elizabeth Head; Eric Doran; Mihaela Nistor; MaryAnn Hill; Frederick A Schmitt; Richard J Haier; Ira T Lott Journal: J Alzheimers Dis Date: 2011 Impact factor: 4.472
Authors: Winnie Ka Yan Mok; Wilfred Hing-Sang Wong; Gary Tsz Kin Mok; Yoyo Wing Yiu Chu; Frederick Ka Wing Ho; Chun Bong Chow; Patrick Ip; Brian Hon-Yin Chung Journal: Health Qual Life Outcomes Date: 2014-10-14 Impact factor: 3.186
Authors: Laura Del Hoyo; Laura Xicota; Gonzalo Sánchez-Benavides; Aida Cuenca-Royo; Susana de Sola; Klaus Langohr; Ana B Fagundo; Magí Farré; Mara Dierssen; Rafael de la Torre Journal: Front Behav Neurosci Date: 2015-11-18 Impact factor: 3.558